GLAXO WELLCOME IMITREX FOLLOW-ON NARATRIPTAN TO BE "GOLD STANDARD" FORMIGRAINE TOLERABILITY, COMPANY TELLS ANALYSTS; SEPTIC SHOCK DRUG IN PHASE III
Executive Summary
Glaxo Wellcome is hoping to position its second migraine product, naratriptan, as the "gold standard" for tolerability while maintaining Imitrex (sumatriptan) as the standard for efficacy, Migraine Product Development Team Leader Kate Lloyd, MD, told an R&D update for analysts in New York City May 5.